{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:54:31Z","timestamp":1768028071535,"version":"3.49.0"},"reference-count":46,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,1,6]]},"DOI":"10.1248\/bpb.b25-00588","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:10:20Z","timestamp":1767651020000},"page":"47-56","source":"Crossref","is-referenced-by-count":0,"title":["Possible Involvement of &lt;i&gt;\u03b2&lt;\/i&gt;&lt;sub&gt;1&lt;\/sub&gt;-Adrenoceptors in the Positive Chronotropic Effects of Mirabegron"],"prefix":"10.1248","volume":"49","author":[{"given":"Kazuo","family":"Noguchi","sequence":"first","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aino","family":"Nagai","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Kashimoto","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuha","family":"Okawa","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Shinkuma","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Inoue","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Kanae","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinami","family":"Ueda","sequence":"additional","affiliation":[{"name":"Laboratory of Functional Food Sciences, Department of Health and Bio-Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, 11\u201368 Koshien Kyuban-cho, Nishinomiya, Hyogo 663\u20138179, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wong YW, Haqqani H, Molenaar P. Roles of \u03b2-adrenoceptor subtypes and therapeutics in human cardiovascular disease: heart failure, tachyarrhythmias and other cardiovascular disorders. <i>Handb. Exp. Pharmacol.<\/i>, <b>285<\/b>, 247\u2013295 (2024).","DOI":"10.1007\/164_2024_720"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Tanaka Y, Horinouchi T, Koike K. New insights into \u03b2-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. <i>Clin. Exp. Pharmacol. Physiol.<\/i>, <b>32<\/b>, 503\u2013514 (2005).","DOI":"10.1111\/j.1440-1681.2005.04222.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pasha A, Tondo A, Favre C, Calvani M. Inside the biology of the \u03b2<sub>3<\/sub>-adrenoceptor. <i>Biomolecules<\/i>, <b>14<\/b>, 159 (2024).","DOI":"10.3390\/biom14020159"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. <i>J. Clin. Invest.<\/i>, <b>98<\/b>, 556\u2013562 (1996).","DOI":"10.1172\/JCI118823"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zhao Q, Zeng F, Liu JB, He Y, Li B, Jiang ZF, Wu TG, Wang LX. Upregulation of \u03b2<sub>3<\/sub>-adrenergic receptor expression in the atrium of rats with chronic heart failure. <i>J. Cardiovasc. Pharmacol. Ther.<\/i>, <b>18<\/b>, 133\u2013137 (2013).","DOI":"10.1177\/1074248412460123"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nakao S, Yanagisawa K, Ueyama T, Hasegawa K, Kawamura T. \u03b2<sub>3<\/sub> adrenergic receptors in the sinoatrial node for heart rate regulation. <i>Eur. Cardiol.<\/i>, <b>16<\/b>, e58 (2021).","DOI":"10.15420\/ecr.2021.16.PO2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Michel MC, Harding SE, Bond RA. Are there functional \u03b2<sub>3<\/sub>-adrenoceptors in the human heart? <i>Br. J. Pharmacol.<\/i>, <b>162<\/b>, 817\u2013822 (2011).","DOI":"10.1111\/j.1476-5381.2010.01005.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Suzuki M, Ukai M, Sasamata M, Seki N. Pharmacological and clinical profile of mirabegron (Betanis\u00ae): a new therapeutic agent for overactive bladder. <i>Nihon Yakurigaku Zasshi<\/i>, <b>139<\/b>, 219\u2013225 (2012).","DOI":"10.1254\/fpj.139.219"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kwon J, Kim DY, Cho KJ, Hashimoto M, Matsuoka K, Kamijo T, Wang Z, Karnup S, Robertson AM, Tyagi P, Yoshimura N. Pathophysiology of overactive bladder and pharmacologic treatments including \u03b2<sub>3<\/sub>-adrenoceptor agonists\u2014basic research perspectives. <i>Int. Neurourol. J.<\/i>, <b>28<\/b><b> (<\/b>Suppl. 1<b>)<\/b>, 12\u201333 (2024).","DOI":"10.5213\/inj.2448002.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S. Evidence for \u03b2<sub>3<\/sub>-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>288<\/b>, 1367\u20131373 (1999).","DOI":"10.1016\/S0022-3565(24)38094-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Katoh T, Kuwamoto K, Kato D, Kuroishi K. Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: results of a Japanese post-marketing study. <i>Int. J. Urol.<\/i>, <b>23<\/b>, 1009\u20131015 (2016).","DOI":"10.1111\/iju.13218"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Andersson KE. Cardiovascular effects of mirabegron. <i>Nat. Rev. Urol.<\/i>, <b>14<\/b>, 587\u2013588 (2017).","DOI":"10.1038\/nrurol.2017.113"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P. The \u03b2<sub>3<\/sub>-adrenoceptor agonist mirabegron increases human atrial force through \u03b2<sub>1<\/sub>-adrenoceptors: an indirect mechanism? <i>Br. J. Pharmacol.<\/i>, <b>174<\/b>, 2706\u20132715 (2017).","DOI":"10.1111\/bph.13897"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) van Gelderen M, St\u00f6lzel M, Meijer J, Kerbusch V, Collins C, Korstanje C. An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects. <i>J. Clin. Pharmacol.<\/i>, <b>57<\/b>, 1534\u20131544 (2017).","DOI":"10.1002\/jcph.952"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. <i>Br. J. Pharmacol. Chemother.<\/i>, <b>14<\/b>, 48\u201358 (1959).","DOI":"10.1111\/j.1476-5381.1959.tb00928.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Biswas S, Malik AH, Bandyopadhyay D, Gupta R, Goel A, Briasoulis A, Fonarow GC, Lanier GM, Naidu SS. Meta-analysis comparing the efficacy of dobutamine <i>versus<\/i> milrinone in acute decompensated heart failure and cardiogenic shock. <i>Curr. Probl. Cardiol.<\/i>, <b>48<\/b>, 101245 (2023).","DOI":"10.1016\/j.cpcardiol.2022.101245"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Su M, Paknejad N, Zhu L, Wang J, Do HN, Miao Y, Liu W, Hite RK, Huang XY. Structures of \u03b2<sub>1<\/sub>-adrenergic receptor in complex with Gs and ligands of different efficacies. <i>Nat. Commun.<\/i>, <b>13<\/b>, 4095 (2022).","DOI":"10.1038\/s41467-022-31823-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Baker JG. The selectivity of \u03b2-adrenoceptor agonists at human \u03b2<sub>1<\/sub>-, \u03b2<sub>2<\/sub>- and \u03b2<sub>3<\/sub>-adrenoceptors. <i>Br. J. Pharmacol.<\/i>, <b>160<\/b>, 1048\u20131061 (2010).","DOI":"10.1111\/j.1476-5381.2010.00754.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Cullum VA, Farmer JB, Jack D, Levy GP. Salbutamol: a new, selective \u03b2-adrenoceptive receptor stimulant. <i>Br. J. Pharmacol.<\/i>, <b>35<\/b>, 141\u2013151 (1969).","DOI":"10.1111\/j.1476-5381.1969.tb07975.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Marques L, Vale N. Salbutamol in the management of asthma: a review. <i>Int. J. Mol. Sci.<\/i>, <b>23<\/b>, 14207 (2022).","DOI":"10.3390\/ijms232214207"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Soares AG, Teixeira SA, Thakore P, Santos LG, Filho WDRP, Antunes VR, Muscar\u00e1 MN, Brain SD, Costa SKP. Disruption of atrial rhythmicity by the air pollutant 1,2-naphthoquinone: role of beta-adrenergic and sensory receptors. <i>Biomolecules<\/i>, <b>14<\/b>, 57 (2023).","DOI":"10.3390\/biom14010057"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and \u03b2 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. <i>Jpn. J. Pharmacol.<\/i>, <b>57<\/b>, 175\u2013185 (1991).","DOI":"10.1254\/jjp.57.175"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Schwartz DD, Naff BP. Activation of protein kinase C by angiotensin II decreases \u03b2<sub>1<\/sub>-adrenergic receptor responsiveness in the rat heart. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>29<\/b>, 257\u2013264 (1997).","DOI":"10.1097\/00005344-199702000-00015"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Akahane K, Furukawa Y, Ogiwara Y, Haniuda M, Chiba S. Beta-2 adrenoceptor-mediated effects on sinus rate and atrial and ventricular contractility on isolated, blood-perfused dog heart preparations. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>248<\/b>, 1276\u20131282 (1989).","DOI":"10.1016\/S0022-3565(25)24152-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Heubach JF, Trebess I, Wettwer E, Himmel HM, Michel MC, Kaumann AJ, Koch WJ, Harding SE, Ravens U. L-type calcium current and contractility in ventricular myocytes from mice overexpressing the cardiac \u03b2<sub>2<\/sub>-adrenoceptor. <i>Cardiovasc. Res.<\/i>, <b>42<\/b>, 173\u2013182 (1999).","DOI":"10.1016\/S0008-6363(98)00262-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. <i>J. Pharmacol. Sci.<\/i>, <b>100<\/b>, 323\u2013337 (2006).","DOI":"10.1254\/jphs.CRJ06001X"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Galindo-Tovar A, Kaumann AJ. Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (\u2013)-adrenaline mediated through mouse cardiac \u03b2<sub>1<\/sub>-adrenoceptors. <i>Br. J. Pharmacol.<\/i>, <b>153<\/b>, 710\u2013720 (2008).","DOI":"10.1038\/sj.bjp.0707631"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Tasler S, Baumgartner R, Behr-Roussel D, Oger-Roussel S, Gorny D, Giuliano F, Ney P. An aryloxypropanolamine h\u03b23-adrenoceptor agonist as bladder smooth muscle relaxant. <i>Eur. J. Pharm. Sci.<\/i>, <b>46<\/b>, 381\u2013387 (2012).","DOI":"10.1016\/j.ejps.2012.03.001"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. Effect of (<i>R<\/i>)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b2<sub>3<\/sub>-adrenoceptor agonist, on bladder function. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>32<\/b>, 642\u2013647 (2007).","DOI":"10.1124\/jpet.106.115840"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Korstanje C, Suzuki M, Yuno K, Sato S, Ukai M, Schneidkraut MJ, Yan GX. Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>87<\/b>, 74\u201381 (2017).","DOI":"10.1016\/j.vascn.2017.04.008"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Iitsuka H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T. Pharmacokinetics of mirabegron, a \u03b2<sub>3<\/sub>-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects. <i>Clin. Ther.<\/i>, <b>37<\/b>, 1031\u20131044 (2015).","DOI":"10.1016\/j.clinthera.2015.02.021"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, Michel MC. The new radioligand [<sup>3<\/sup>H]-L748,337 differentially labels human and rat \u03b2<sub>3<\/sub>-adrenoceptors. <i>Eur. J. Pharmacol.<\/i>, <b>720<\/b>, 124\u2013130 (2013).","DOI":"10.1016\/j.ejphar.2013.10.039"},{"key":"33","unstructured":"33) Baker JG. The selectivity of \u03b2-adrenoceptor antagonists at the human \u03b2<sub>1<\/sub>, \u03b2<sub>2<\/sub> and \u03b2<sub>3<\/sub> adrenoceptors. <i>Br. J. Pharmacol.<\/i>, <b>144<\/b>, 317\u2013322 (2005)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Sasamata M. <i>In vitro<\/i> and <i>in vivo<\/i> pharmacological profile of the selective \u03b2<sub>3<\/sub>-adrenoceptor agonist mirabegron in rats. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>386<\/b>, 247\u2013253 (2013).","DOI":"10.1007\/s00210-012-0821-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Myslivecek J, Tillinger A, Novakova M, Kvetnansk\u00fd R. Regulation of adrenoceptor and muscarinic receptor gene expression after single and repeated stress. <i>Ann. N. Y. Acad. Sci.<\/i>, <b>1148<\/b>, 367\u2013376 (2008).","DOI":"10.1196\/annals.1410.028"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Yamada S, Niiya R, Ito Y, Kato Y, Onoue S. Comparative characterization of \u03b2-adrenoceptors in the bladder, heart, and lungs of rats: alterations in spontaneously hypertensive rats. <i>J. Pharmacol. Sci.<\/i>, <b>148<\/b>, 51\u201355 (2022).","DOI":"10.1016\/j.jphs.2021.10.003"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Sykes DA, Jim\u00e9nez-Ros\u00e9s M, Reilly J, Fairhurst RA, Charlton SJ, Veprintsev DB. Exploring the kinetic selectivity of drugs targeting the \u03b2<sub>1<\/sub>-adrenoceptor. <i>Pharmacol. Res. Perspect.<\/i>, <b>10<\/b>, e00978 (2022).","DOI":"10.1002\/prp2.978"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Levy FO, Zhu X, Kaumann AJ, Birnbaumer L. Efficacy of beta 1-adrenergic receptors is lower than that of \u03b2 2-adrenergic receptors. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>90<\/b>, 10798\u201310802 (1993).","DOI":"10.1073\/pnas.90.22.10798"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kitagawa Y, Adachi-Akahane S, Nagao T. Determination of \u03b2-adrenoceptor subtype on rat isolated ventricular myocytes by use of highly selective beta-antagonists. <i>Br. J. Pharmacol.<\/i>, <b>116<\/b>, 1635\u20131643 (1995).","DOI":"10.1111\/j.1476-5381.1995.tb16384.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Engelhardt S, Grimmer Y, Fan GH, Lohse MJ. Constitutive activity of the human \u03b2<sub>1<\/sub>-adrenergic receptor in \u03b2<sub>1<\/sub>-receptor transgenic mice. <i>Mol. Pharmacol.<\/i>, <b>60<\/b>, 712\u2013717 (2001).","DOI":"10.1016\/S0026-895X(24)12297-3"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Janssens K, Boussemaere M, Wagner S, Kopka K, Denef C. \u03b2<sub>1<\/sub>-Adrenoceptors in rat anterior pituitary may be constitutively active. Inverse agonism of CGP 20712A on basal 3\u2032,5\u2032-cyclic adenosine 5\u2032-monophosphate levels. <i>Endocrinology<\/i>, <b>149<\/b>, 2391\u20132402 (2008).","DOI":"10.1210\/en.2007-1397"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Giraldo J, Serra J, Roche D, Rovira X. Assessing receptor affinity for inverse agonists: Schild and Cheng-Prusoff methods revisited. <i>Curr. Drug Targets<\/i>, <b>8<\/b>, 197\u2013202 (2007).","DOI":"10.2174\/138945007779315687"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. Vibegron shows high selectivity and potent agonist activity for \u03b2<sub>3<\/sub>-adrenoceptors, irrespective of receptor density. <i>PLOS ONE<\/i>, <b>18<\/b>, e0290685 (2023).","DOI":"10.1371\/journal.pone.0290685"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b2<sub>3<\/sub>-adrenoceptor agonist. <i>Xenobiotica<\/i>, <b>42<\/b>, 957\u2013967 (2012).","DOI":"10.3109\/00498254.2012.675095"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular Safety of \u03b2<sub>3<\/sub>-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. <i>Eur. Urol.<\/i>, <b>69<\/b>, 311\u2013323 (2016).","DOI":"10.1016\/j.eururo.2015.09.007"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Michel MC, Gravas S. Safety and tolerability of \u03b2<sub>3<\/sub>-adrenoceptor agonists in the treatment of overactive bladder syndrome\u2014insight from transcriptosome and experimental studies. <i>Expert Opin. Drug Saf.<\/i>, <b>15<\/b>, 647\u2013657 (2016).","DOI":"10.1517\/14740338.2016.1160055"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/1\/49_b25-00588\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:29:53Z","timestamp":1768015793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/1\/49_b25-00588\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00588","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"b25-00588"}}